Publicacións nas que colabora con Enrique Grande Pulido (23)

2023

  1. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

    Prostate, Vol. 83, Núm. 4, pp. 376-384

2022

  1. Corrigendum to “589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)”: [Annals of Oncology 32 suppl. 5 (2021) S637-S638] (Annals of Oncology (2021) 32 suppl. 5(S637-S638) (S0923753421033317), (10.1016/j.annonc.2021.08.1102))

    Annals of Oncology

  2. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study

    Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100

2019

  1. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: A pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    BMC Cancer, Vol. 19, Núm. 1

  2. The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)

    Targeted Oncology, Vol. 14, Núm. 1, pp. 15-32

2018

  1. Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib

    Oncotarget, Vol. 9, Núm. 97, pp. 36894-36905

  2. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies

    Expert Opinion on Drug Safety, Vol. 17, Núm. 6, pp. 573-579

2017

  1. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, Núm. 7, pp. 1517-1522

  2. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study

    Annals of Oncology, Vol. 28, Núm. 7, pp. 1-9

  3. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment

    Critical Reviews in Oncology/Hematology, Vol. 113, pp. 171-190

2015

  1. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: A retrospective cross-sectional analysis

    BMC Cancer, Vol. 15, Núm. 1

2014

  1. Stem cells in cancer: Should we believe or not?

    Springer Netherlands, pp. 1-299

  2. The universal stem cell source: Does it exist?

    Stem Cells in Cancer: Should We Believe or Not? (Springer Netherlands), pp. 1-22

2012

  1. A primary signet ring cell carcinoma of the prostate with bone metastasis with impressive response to FOLFOX and cetuximab

    Clinical Genitourinary Cancer, Vol. 10, Núm. 3, pp. 199-201

  2. Crossing paths in human renal cell carcinoma (hRCC)

    International Journal of Molecular Sciences, Vol. 13, Núm. 10, pp. 12710-12733

  3. Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?

    Cancer metastasis reviews, Vol. 31, Núm. 1-2, pp. 47-53

  4. Sunitinib: The first to arrive at first-line metastatic renal cell carcinoma

    Advances in Therapy, Vol. 29, Núm. 3, pp. 202-217

2011

  1. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients

    Expert Opinion on Pharmacotherapy, Vol. 12, Núm. 16, pp. 2433-2439

  2. Fructose transporter GLUT5 expression in clear renal cell carcinoma

    Oncology Reports, Vol. 25, Núm. 2, pp. 315-323

  3. New insights into molecular mechanisms of sunitinib-associated side effects

    Molecular Cancer Therapeutics, Vol. 10, Núm. 12, pp. 2215-2223